Back to Search
Start Over
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
- Source :
- Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
- Publication Year :
- 2021
- Publisher :
- Nature Portfolio, 2021.
-
Abstract
- The 3CL protease of SARS-CoV-2 is inhibited by PF-00835231 in vitro. Here, the authors show that the prodrug PF-07304814 has broad spectrum activity, inhibiting SARS-CoV and SARS-CoV-2 in mice and its ADME and safety profile support clinical development.
- Subjects :
- Science
Subjects
Details
- Language :
- English
- ISSN :
- 20411723
- Volume :
- 12
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nature Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7c0ac56767d64fb5af7714d7f3a62322
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41467-021-26239-2